Cell survival signaling in neuroblastoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 563-575

  Megison, Michael L ^a   Gillory, Lauren A ^a   Beierle, Elizabeth A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cell survival; Kinases; Neuroblastoma; Phosphorylate; Transcription factors

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL) AMINO] PYRROLO [2, 1 F] [1, 2, 4] TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; AEW 541; AXITINIB; CEDIRANIB; CRIZOTINIB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FOCAL ADHESION KINASE; GEFITINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; MYC PROTEIN; NVP AEW 541; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; TAE 684; TEMSIROLIMUS; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; Y 15;

APOPTOSIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; DOWN REGULATION; FIBROBLAST; HUMAN; NEUROBLASTOMA; OXIDATIVE STRESS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROBLASTOMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84876701881     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313040005     Document Type: Review

References (153)

1. Spix, C.; Pastore, G.; Sankila, R.; Stiller, C. A.; Steliarova-Foucher, E. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur. J. Cancer, 2006, 42 (13), 2081-91.
2. Maris, J. M.; Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol., 1999, 17 (7), 2264-2279.
3. Cotterill, S. J.; Parker, L.; More, L.; Craft, A. W. Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry. Med. Pediatr. Oncol., 2001, 36 (1), 231-234.
4. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev., 1999, 13 (22), 2905-2927.
5. Scott, P. H.; Brunn, G. J.; Kohn, A. D.; Roth, R. A.; Lawrence, J. C. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. U. S. A., 1998, 95 (13), 7772-7777.
6. Liang, J.; Zubovitz, J.; Petrocelli, T.; Kotchetkov, R.; Connor, M. K.; Han, K.; Lee, J. H.; Ciarallo, S.; Catzavelos, C.; Beniston, R.; Franssen, E.; Slingerland, J. M. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med., 2002, 8 (10), 1153-1160.
7. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 1997, 91 (2), 231-241.
8. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999, 399 (6736), 601-605.
9. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol., 1997, 7 (4), 261-269.
10. Bellacosa, A.; Testa, J. R.; Staal, S. P.; Tsichlis, P. N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science, 1991, 254 (5029), 274-277.
11. Dudek, H.; Datta, S. R.; Franke, T. F.; Birnbaum, M. J.; Yao, R.; Cooper, G. M.; Segal, R. A.; Kaplan, D. R.; Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 1997, 275 (5300), 661-665.
12. Khwaja, A.; Rodriguez-Viciana, P.; Wennström, S.; Warne, P. H.; Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J., 1997, 16 (10), 2783-2793.
13. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4 (12), 988-1004.
14. Johnsen, J. I.; Segerström, L.; Orrego, A.; Elfman, L.; Henriksson, M.; Kågedal, B.; Eksborg, S.; Sveinbjörnsson, B.; Kogner, P. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene, 2008, 27 (20), 2910-2922.
15. Opel, D.; Poremba, C.; Simon, T.; Debatin, K. M.; Fulda, S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res., 2007, 67 (2), 735-745.
16. Shi, C.; Wu, F.; Yew, D. T.; Xu, J.; Zhu, Y. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Apoptosis, 2010, 15 (6), 715-727.
17. Kwon, S. H.; Hong, S. I.; Kim, J. A.; Jung, Y. H.; Kim, S. Y.; Kim, H. C.; Lee, S. Y.; Jang, C. G. The neuroprotective effects of Lonicera japonica THUNB. against hydrogen peroxide-induced apoptosis via phosphorylation of MAPKs and PI3K/Akt in SH-SY5Y cells. Food Chem. Toxicol., 2011, 49 (4), 1011-1019.
18. Dedoni, S.; Olianas, M. C.; Onali, P. Interferon-induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway. J. Neurochem., 2010, 115 (6), 1421-1433.
19. Cully, M.; You, H.; Levine, A. J.; Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer, 2006, 6 (3), 184-192.
20. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 2005, 8 (3), 179-183.
21. Segerström, L.; Baryawno, N.; Sveinbjörnsson, B.; Wickström, M.; Elfman, L.; Kogner, P.; Johnsen, J. I. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int. J. Cancer, 2011, 129 (12), 2958-2965.
22. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer, 2003, 3 (3), 203-216.
23. Brodeur, G. M.; Seeger, R. C.; Schwab, M.; Varmus, H. E.; Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 1984, 224 (4653), 1121-1124.
24. Kondapaka, S. B.; Singh, S. S.; Dasmahapatra, G. P.; Sausville, E. A.; Roy, K. K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther., 2003, 2 (11), 1093-1103.
25. Sun, W.; Modak, S. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther., 2012, 5, 21-29.
26. Li, Z.; Oh, D. Y.; Nakamura, K.; Thiele, C. J. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer, 2011, 117 (23), 5412-5422.
27. Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K. G.; Shapiro, D. N.; Saltman, D. L.; Look, A. T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 1994, 263 (5151), 1281-1284.
28. Palmer, R. H.; Vernersson, E.; Grabbe, C.; Hallberg, B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J., 2009, 420 (3), 345-361.
29. Griffin, C. A.; Hawkins, A. L.; Dvorak, C.; Henkle, C.; Ellingham, T.; Perlman, E. J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res., 1999, 59 (12), 2776-2780.
30. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448 (7153), 561-566.
31. Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; Macneill, J.; Ren, J. M.; Yuan, J.; Bakalarski, C. E.; Villen, J.; Kornhauser, J. M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S. P.; Gu, T. L.; Polakiewicz, R. D.; Rush, J.; Comb, M. J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131 (6), 1190-1203.
32. Arber, D. A.; Sun, L. H.; Weiss, L. M. Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum. Pathol., 1996, 27 (6), 590-594.
33. Du, X. L.; Hu, H.; Lin, D. C.; Xia, S. H.; Shen, X. M.; Zhang, Y.; Luo, M. L.; Feng, Y. B.; Cai, Y.; Xu, X.; Han, Y. L.; Zhan, Q. M.; Wang, M. R. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J. Mol. Med. (Berl), 2007, 85 (8), 863-875.
34. Jazii, F. R.; Najafi, Z.; Malekzadeh, R.; Conrads, T. P.; Ziaee, A. A.; Abnet, C.; Yazdznbod, M.; Karkhane, A. A.; Salekdeh, G. H. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J. Gastroenterol., 2006, 12 (44), 7104-7112.
35. Lamant, L.; Pulford, K.; Bischof, D.; Morris, S. W.; Mason, D. Y.; Delsol, G.; Mariamé, B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol., 2000, 156 (5), 1711-1721.
36. Passoni, L.; Longo, L.; Collini, P.; Coluccia, A. M.; Bozzi, F.; Podda, M.; Gregorio, A.; Gambini, C.; Garaventa, A.; Pistoia, V.; Del Grosso, F.; Tonini, G. P.; Cheng, M.; Gambacorti-Passerini, C.; Anichini, A.; Fossati-Bellani, F.; Di Nicola, M.; Luksch, R. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res., 2009, 69 (18), 7338-7346.
37. Mossé, Y. P.; Laudenslager, M.; Longo, L.; Cole, K. A.; Wood, A.; Attiyeh, E. F.; Laquaglia, M. J.; Sennett, R.; Lynch, J. E.; Perri, P.; Laureys, G.; Speleman, F.; Kim, C.; Hou, C.; Hakonarson, H.; Torkamani, A.; Schork, N. J.; Brodeur, G. M.; Tonini, G. P.; Rappaport, E.; Devoto, M.; Maris, J. M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008, 455 (7215), 930-935.
38. De Brouwer, S.; De Preter, K.; Kumps, C.; Zabrocki, P.; Porcu, M.; Westerhout, E. M.; Lakeman, A.; Vandesompele, J.; Hoebeeck, J.; Van Maerken, T.; De Paepe, A.; Laureys, G.; Schulte, J. H.; Schramm, A.; Van Den Broecke, C.; Vermeulen, J.; Van Roy, N.; Beiske, K.; Renard, M.; Noguera, R.; Delattre, O.; Janoueix-Lerosey, I.; Kogner, P.; Martinsson, T.; Nakagawara, A.; Ohira, M.; Caron, H.; Eggert, A.; Cools, J.; Versteeg, R.; Speleman, F. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res., 2010, 16 (17), 4353-4362.
39. Schönherr, C.; Ruuth, K.; Kamaraj, S.; Wang, C. L.; Yang, H. L.; Combaret, V.; Djos, A.; Martinsson, T.; Christensen, J. G.; Palmer, R. H.; Hallberg, B. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene, 2012, 31(50),5193-200.
40. Del Grosso, F.; De Mariano, M.; Passoni, L.; Luksch, R.; Tonini, G. P.; Longo, L. Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines. BMC Cancer, 2011, 11, 525.
41. Gabarra-Niecko, V.; Schaller, M. D.; Dunty, J. M. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev., 2003, 22 (4), 359-74.
42. Xu, L. H.; Yang, X.; Bradham, C. A.; Brenner, D. A.; Baldwin, A. S.; Craven, R. J.; Cance, W. G. The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J. Biol. Chem., 2000, 275 (39), 30597-30604.
43. Xu, L. H.; Yang, X.; Craven, R. J.; Cance, W. G. The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ., 1998, 9 (12), 999-1005.
44. Xu, L. H.; Owens, L. V.; Sturge, G. C.; Yang, X.; Liu, E. T.; Craven, R. J.; Cance, W. G., Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ., 1996, 7 (4), 413-418.
45. Golubovskaya, V.; Beviglia, L.; Xu, L. H.; Earp, H. S.; Craven, R.; Cance, W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J. Biol. Chem., 2002, 277 (41), 38978-38987.
46. Beierle, E. A.; Trujillo, A.; Nagaram, A.; Kurenova, E. V.; Finch, R.; Ma, X.; Vella, J.; Cance, W. G.; Golubovskaya, V. M. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J. Biol. Chem., 2007, 282 (17), 12503-12516.
47. Beierle, E. A.; Massoll, N. A.; Hartwich, J.; Kurenova, E. V.; Golubovskaya, V. M.; Cance, W. G.; McGrady, P.; London, W. B. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin. Cancer Res., 2008, 14 (11), 3299-3305.
48. Golubovskaya, V.; Kaur, A.; Cance, W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim. Biophys. Acta, 2004, 1678 (2-3), 111-125.
49. Beierle, E. A.; Ma, X.; Trujillo, A.; Kurenova, E. V.; Cance, W. G.; Golubovskaya, V. M. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol. Carcinog., 2010, 49 (3), 224-234.
50. Beierle, E. A.; Trujillo, A.; Nagaram, A.; Golubovskaya, V. M.; Cance, W. G.; Kurenova, E. V. TAE226 inhibits human neuroblastoma cell survival. Cancer Invest., 2008, 26 (2), 145-251.
51. Beierle, E. A.; Ma, X.; Stewart, J.; Nyberg, C.; Trujillo, A.; Cance, W. G.; Golubovskaya, V. M. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle, 2010, 9 (5), 1005-1015.
52. Schultze, A.; Fiedler, W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin. Investig. Drug., 2010, 19 (6), 777-788.
53. Baeuerle, P. A.; Baltimore, D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science, 1988, 242 (4878), 540-546.
54. Lenardo, M. J.; Baltimore, D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell, 1989, 58 (2), 227-229.
55. Beauparlant, P.; Kwan, I.; Bitar, R.; Chou, P.; Koromilas, A. E.; Sonenberg, N.; Hiscott, J. Disruption of I kappa B alpha regulation by antisense RNA expression leads to malignant transformation. Oncogene, 1994, 9 (11), 3189-3197.
56. Beg, A. A.; Baltimore, D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science, 1996, 274 (5288), 782-784.
57. Mitsiades, C. S.; Mitsiades, N.; Poulaki, V.; Schlossman, R.; Akiyama, M.; Chauhan, D.; Hideshima, T.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 2002, 21 (37), 5673-5683.
58. Körner, M.; Tarantino, N.; Pleskoff, O.; Lee, L. M.; Debré, P. Activation of nuclear factor kappa B in human neuroblastoma cell lines. J. Neurochem., 1994, 62 (5), 1716-1726.
59. Russo, V. C.; Kobayashi, K.; Najdovska, S.; Baker, N. L.; Werther, G. A. Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system. Brain Res., 2004, 1009 (1-2), 40-53.
60. Ammann, J. U.; Haag, C.; Kasperczyk, H.; Debatin, K. M.; Fulda, S. Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition. Int. J. Cancer, 2009, 124 (6), 1301-1311.
61. Karacay, B.; Sanlioglu, S.; Griffith, T. S.; Sandler, A.; Bonthius, D. J. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther., 2004, 11 (10), 681-690.
62. Gao, X.; Deeb, D.; Jiang, H.; Liu, Y.; Dulchavsky, S. A.; Gautam, S. C., Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J. Neurooncol., 2007, 84 (2), 147-157.
63. Orr, W. S.; Denbo, J. W.; Saab, K. R.; Myers, A. L.; Ng, C. Y.; Zhou, J.; Morton, C. L.; Pfeffer, L. M.; Davidoff, A. M.; Grandori, C.; Cowley, S. M.; James, L. P.; Eisenman, R. N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol., 2000, 16, 653-699.
64. Zimmerman, K. A.; Yancopoulos, G. D.; Collum, R. G.; Smith, R. K.; Kohl, N. E.; Denis, K. A.; Nau, M. M.; Witte, O. N.; Toran-Allerand, D.; Gee, C. E. Differential expression of myc family genes during murine development. Nature, 1986, 319 (6056), 780-783.
65. Strieder, V.; Lutz, W. Regulation of N-myc expression in development and disease. Cancer Lett., 2002, 180 (2), 107-119.
66. Weiss, W. A.; Aldape, K.; Mohapatra, G.; Feuerstein, B. G.; Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J., 1997, 16 (11), 2985-95.
67. Brodeur, G. M. Neuroblastoma: clinical significance of genetic abnormalities. Cancer Surv., 1990, 9 (4), 673-688.
68. Burkhart, C. A.; Cheng, A. J.; Madafiglio, J.; Kavallaris, M.; Mili, M.; Marshall, G. M.; Weiss, W. A.; Khachigian, L. M.; Norris, M. D.; Haber, M. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J. Natl. Cancer Inst., 2003, 95 (18), 1394-1403.
69. Kang, J. H.; Rychahou, P. G.; Ishola, T. A.; Qiao, J.; Evers, B. M.; Chung, D. H. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem. Biophys. Res. Commun.,2006, 351 (1), 192-197.
70. Tonelli, R.; Purgato, S.; Camerin, C.; Fronza, R.; Bologna, F.; Alboresi, S.; Franzoni, M.; Corradini, R.; Sforza, S.; Faccini, A.; Shohet, J. M.; Marchelli, R.; Pession, A. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol. Cancer Ther., 2005, 4 (5), 779-86.
71. Pession, A.; Tonelli, R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr. Cancer Drug Targets, 2005, 5 (4), 273-283.
72. Lynch, J.; Fay, J.; Meehan, M.; Bryan, K.; Watters, K. M.; Murphy, D. M.; Stallings, R. L. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-ignalling pathway. Carcinogenesis, 2012, 33(5), 976-85
73. Buechner, J.; Tømte, E.; Haug, B. H.; Henriksen, J. R.; Løkke, C.; Flægstad, T.; Einvik, C. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br. J. Cancer, 2011, 105 (2), 296-303.
74. Cohn, S. L.; London, W. B.; Huang, D.; Katzenstein, H. M.; Salwen, H. R.; Reinhart, T.; Madafiglio, J.; Marshall, G. M.; Norris, M. D.; Haber, M. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol., 2000, 18 (21), 3604-3613.
75. Torres, J.; Regan, P. L.; Edo, R.; Leonhardt, P.; Jeng, E. I.; Rappaport, E. F.; Ikegaki, N.; Tang, X. X. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Int. J. Oncol., 2010, 37 (4), 983-991.
76. Lu, X.; Pearson, A.; Lunec, J. The MYCN oncoprotein as a drug development target. Cancer Lett., 2003, 197 (1-2), 125-130.
77. Miyashita, T.; Krajewski, S.; Krajewska, M.; Wang, H. G.; Lin, H. K.; Liebermann, D. A.; Hoffman, B.; Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 1994, 9 (6), 1799-1805.
78. Kastan, M. B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 1991, 51 (23 Pt 1), 6304-6311.
79. Graeber, T. G.; Osmanian, C.; Jacks, T.; Housman, D. E.; Koch, C. J.; Lowe, S. W.; Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996, 379 (6560), 88-91.
80. Hollstein, M.; Rice, K.; Greenblatt, M. S.; Soussi, T.; Fuchs, R.; Sørlie, T.; Hovig, E.; Smith-Sørensen, B.; Montesano, R.; Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 1994, 22 (17), 3551-3555.
81. Imamura, J.; Bartram, C. R.; Berthold, F.; Harms, D.; Nakamura, H.; Koeffler, H. P. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 1993, 53 (17), 4053-8.
82. Vogan, K.; Bernstein, M.; Leclerc, J. M.; Brisson, L.; Brossard, J.; Brodeur, G. M.; Pelletier, J.; Gros, P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res., 1993, 53 (21), 5269-5273.
83. Manhani, R.; Cristofani, L. M.; Odone Filho, V.; Bendit, I. Concomitant p53 mutation and MYCN amplification in neuroblastoma. Med. Pediatr. Oncol., 1997, 29 (3), 206-207.
84. Regan, P. L.; Jacobs, J.; Wang, G.; Torres, J.; Edo, R.; Friedmann, J.; Tang, X. X. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int. J. Oncol., 2011, 38 (1), 105-112.
85. Chen, L.; Iraci, N.; Gherardi, S.; Gamble, L. D.; Wood, K. M.; Perini, G.; Lunec, J.; Tweddle, D. A. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res., 2010, 70 (4), 1377-1388.
86. Chen, J.; Wu, X.; Lin, J.; Levine, A. J., mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996, 16 (5), 2445-52.
87. de Oca L. R. M.; Wagner, D. S.; Lozano, G., Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378 (6553), 203-6.
88. Corvi, R.; Savelyeva, L.; Breit, S.; Wenzel, A.; Handgretinger, R.; Barak, J.; Oren, M.; Amler, L.; Schwab, M. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene, 1995, 10 (6), 1081-1086.
89. Cattelani, S.; Defferrari, R.; Marsilio, S.; Bussolari, R.; Candini, O.; Corradini, F.; Ferrari-Amorotti, G.; Guerzoni, C.; Pecorari, L.; Menin, C.; Bertorelle, R.; Altavista, P.; McDowell, H. P.; Boldrini, R.; Dominici, C.; Tonini, G. P.; Raschellà, G.; Calabretta, B. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients. Clin. Cancer Res., 2008, 14 (11), 3248-3253.
90. Slack, A.; Chen, Z.; Tonelli, R.; Pule, M.; Hunt, L.; Pession, A.; Shohet, J. M. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl. Acad. Sci. U. S. A., 2005, 102 (3), 731-736.
91. Gu, L.; Zhang, H.; He, J.; Li, J.; Huang, M.; Zhou, M. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene, 2012, 31 (11), 1342-1353.
92. He, J.; Gu, L.; Zhang, H.; Zhou, M. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. Cell Cycle, 2011, 10 (17), 2994-3002.
93. Chen, Z.; Lin, Y.; Barbieri, E.; Burlingame, S.; Hicks, J.; Ludwig, A.; Shohet, J. M. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia, 2009, 11 (8), 753-762.
94. Golubovskaya, V. M.; Finch, R.; Kweh, F.; Massoll, N. A.; Campbell-Thompson, M.; Wallace, M. R.; Cance, W. G. p53 regulates FAK expression in human tumor cells. Mol. Carcinog., 2008, 47 (5), 373-382.
95. Golubovskaya, V. M.; Finch, R.; Zheng, M.; Kurenova, E. V.; Cance, W. G. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning. Biochem. J., 2008, 411 (1), 151-160.
96. Golubovskaya, V.; Palma, N. L.; Zheng, M.; Ho, B.; Magis, A.; Ostrov, D.; Cance, W. G. A Small-Molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK And Mdm-2 Interaction, And Blocks Breast And Colon Tumorigenesis In Vivo. Anticancer Agents Med. Chem., 2012, In press
97. Mattsson, M. E.; Enberg, G.; Ruusala, A. I.; Hall, K.; Påhlman, S. Mitogenic response of human SH-SY5Y neuroblastoma cells to insulin-like growth factor I and II is dependent on the stage of differentiation. J. Cell. Biol., 1986, 102 (5), 1949-1954.
98. Sullivan, K. A.; Castle, V. P.; Hanash, S. M.; Feldman, E. L. Insulin-like growth factor II in the pathogenesis of human neuroblastoma. Am. J. Pathol., 1995, 147 (6), 1790-1798.
99. Tanno, B.; Mancini, C.; Vitali, R.; Mancuso, M.; McDowell, H. P.; Dominici, C.; Raschellà, G., Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 2006, 12 (22), 6772-80.
100. Chambéry, D.; Mohseni-Zadeh, S.; de Gallé, B.; Babajko, S. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res., 1999, 59 (12), 2898-2902.
101. Matthews, C. C.; Feldman, E. L. Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J. Cell. Physiol., 1996, 166 (2), 323-31.
102. Kim, B.; Feldman, E. L. Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J. Biol. Chem., 2002, 277 (30), 27393-27400.
103. Wang, L.; Yang, H. J.; Xia, Y. Y.; Feng, Z. W. Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+-induced apoptosis by AKT/GSK-3 /JNK signaling. Apoptosis, 2010, 15 (12), 1470-1479.
104. Lee, Y. H.; White, M. F. Insulin receptor substrate proteins and diabetes. Arch. Pharm. Res., 2004, 27 (4), 361-370.
105. Kim, B.; Feldman, E. L. Insulin receptor substrate (IRS)-2, not IRS-1, protects human neuroblastoma cells against apoptosis. Apoptosis, 2009, 14 (5), 665-673.
106. Stöhr, O.; Hahn, J.; Moll, L.; Leeser, U.; Freude, S.; Bernard, C.; Schilbach, K.; Markl, A.; Udelhoven, M.; Krone, W.; Schubert, M. Insulin receptor substrate-1 and -2 mediate resistance to glucose-induced caspase-3 activation in human neuroblastoma cells. Biochim. Biophys. Acta, 2011, 1812 (5), 573-580.
107. Carboni, J. M.; Wittman, M.; Yang, Z.; Lee, F.; Greer, A.; Hurlburt, W.; Hillerman, S.; Cao, C.; Cantor, G. H.; Dell-John, J.; Chen, C.; Discenza, L.; Menard, K.; Li, A.; Trainor, G.; Vyas, D.; Kramer, R.; Attar, R. M.; Gottardis, M. M. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther., 2009, 8 (12), 3341-3349.
108. Kolb, E. A.; Gorlick, R.; Lock, R.; Carol, H.; Morton, C. L.; Keir, S. T.; Reynolds, C. P.; Kang, M. H.; Maris, J. M.; Billups, C.; Smith, M. A.; Houghton, P. J. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2011, 56 (4), 595-603.
109. Reidy-Lagunes, D. L.; Vakiani, E.; Segal, M. F.; Hollywood, E. M.; Tang, L. H.; Solit, D. B.; Pietanza, M. C.; Capanu, M.; Saltz, L. B. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer, 2012, 118(19),4795-4800
110. Tamura, S.; Hosoi, H.; Kuwahara, Y.; Kikuchi, K.; Otabe, O.; Izumi, M.; Tsuchiya, K.; Iehara, T.; Gotoh, T.; Sugimoto, T. Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochim. Biophys. Res. Commun., 2007, 358 (1), 226-232.
111. Ho, R.; Minturn, J. E.; Hishiki, T.; Zhao, H.; Wang, Q.; Cnaan, A.; Maris, J.; Evans, A. E.; Brodeur, G. M. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res., 2005, 65 (21), 9868-9875.
112. Meyers, M. B.; Shen, W. P.; Spengler, B. A.; Ciccarone, V.; O'Brien, J. P.; Donner, D. B.; Furth, M. E.; Biedler, J. L. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J. Cell. Biochem., 1988, 38 (2), 87-97.
113. da Motta, L. A.; Galli, P.; Piva, F.; Maggi, R. Effects of epidermal growth factor on the [3H]-thymidine uptake in the SK-N-SH and SH-SY5Y human neuroblastoma cell lines. Arq. Neuropsiquiatr., 1997, 55 (3A), 444-451.
114. Hatziagapiou, K.; Braoudaki, M.; Karpusas, M.; Tzortzatou-Stathopoulou, F. Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells. Clin. Lab., 2011, 57 (9-10), 781-784.
115. Donfrancesco, A.; De Ioris, M. A.; McDowell, H. P.; De Pasquale, M. D.; Ilari, I.; Jenkner, A.; Castellano, A.; Cialfi, S.; De Laurentis, C.; Dominici, C. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. Pediatr. Blood Cancer, 2010, 54 (1), 55-61.
116. Rössler, J.; Odenthal, E.; Geoerger, B.; Gerstenmeyer, A.; Lagodny, J.; Niemeyer, C. M.; Vassal, G. EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. Anticancer Res., 2009, 29 (4), 1327-1333.
117. Furman, W. L.; McGregor, L. M.; McCarville, M. B.; Onciu, M.; Davidoff, A. M.; Kovach, S.; Hawkins, D.; McPherson, V.; Houghton, P. J.; Billups, C. A.; Wu, J.; Stewart, C. F.; Santana, V. M. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest. New Drugs, 2011, 30(4),1660-1670
118. Jakacki, R. I.; Hamilton, M.; Gilbertson, R. J.; Blaney, S. M.; Tersak, J.; Krailo, M. D.; Ingle, A. M.; Voss, S. D.; Dancey, J. E.; Adamson, P. C. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: A Children's Oncology Group Phase I Consortium Study. J. Clin. Oncol., 2008, 26 (30), 4921-4927.
119. Sprugel, K. H.; McPherson, J. M.; Clowes, A. W.; Ross, R. Effects of growth factors in vivo. I. Cell ingrowth into porous subcutaneous chambers. Am. J. Pathol., 1987, 129 (3), 601-613.
120. Nistér, M.; Libermann, T. A.; Betsholtz, C.; Pettersson, M.; Claesson-Welsh, L.; Heldin, C. H.; Schlessinger, J.; Westermark, B. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res., 1988, 48 (14), 3910-3918.
121. Påhlman, S.; Johansson, I.; Westermark, B.; Nistér, M. Platelet-derived growth factor potentiates phorbol ester-induced neuronal differentiation of human neuroblastoma cells. Cell Growth Differ., 1992, 3 (11), 783-790.
122. Matsui, T.; Sano, K.; Tsukamoto, T.; Ito, M.; Takaishi, T.; Nakata, H.; Nakamura, H.; Chihara, K. Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. J. Clin. Invest., 1993, 92 (3), 1153-1160.
123. Eggert, A.; Ikegaki, N.; Kwiatkowski, J.; Zhao, H.; Brodeur, G. M.; Himelstein, B. P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res., 2000, 6 (5), 1900-1908.
124. Pola, S.; Cattaneo, M. G.; Vicentini, L. M. Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J. Biol. Chem., 2003, 278 (42), 40601-40606.
125. Lee, M. C.; Lee, W. S.; Park, C. S.; Juhng, S. W. The biologic role of ganglioside in neuronal differentiation--effects of GM1 ganglioside on human neuroblastoma SH-SY5Y cells. J. Korean Med. Sci., 1994, 9 (2), 179-187.
126. Hynds, D. L.; Summers, M.; Van Brocklyn, J.; O'Dorisio, M. S.; Yates, A. J. Gangliosides inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in neuroblastoma SH-SY5Y cells. J. Neurochem., 1995, 65 (5), 2251-2258.
127. Beppu, K.; Jaboine, J.; Merchant, M. S.; Mackall, C. L.; Thiele, C. J. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J. Natl. Cancer Inst., 2004, 96 (1), 46-55.
128. Bond, M.; Bernstein, M. L.; Pappo, A.; Schultz, K. R.; Krailo, M.; Blaney, S. M.; Adamson, P. C. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer, 2008, 50 (2), 254-258.
129. Palmberg, E.; Johnsen, J. I.; Paulsson, J.; Gleissman, H.; Wickström, M.; Edgren, M.; Ostman, A.; Kogner, P.; Lindskog, M. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int. J. Cancer, 2009, 124 (5), 1227-1234.
130. Timeus, F.; Crescenzio, N.; Doria, A.; Foglia, L.; Pagliano, S.; Ricotti, E.; Fagioli, F.; Tovo, P. A.; di Montezemolo, L. In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib. Oncol. Rep., 2012, 27 (3), 734-740.
131. Bäckman, U.; Christofferson, R. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr. Res., 2005, 57 (5 Pt 1), 690-695.
132. Adamson, P. C.; Blaney, S. M.; Widemann, B. C.; Kitchen, B.; Murphy, R. F.; Hannah, A. L.; Cropp, G. F.; Patel, M.; Gillespie, A. F.; Whitcomb, P. G.; Balis, F. M. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother. Pharmacol., 2004, 53 (6), 482-488.
133. van Iterson, V.; Leidenius, M.; von Smitten, K.; Bono, P.; Heikkilä, P. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am. J. Clin. Pathol., 2007, 128 (5), 759-766.
134. Saintigny, P.; Kambouchner, M.; Ly, M.; Gomes, N.; Sainte-Catherine, O.; Vassy, R.; Czernichow, S.; Letoumelin, P.; Breau, J. L.; Bernaudin, J. F.; Kraemer, M. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer, 2007, 58 (2), 205-213.
135. Jennbacken, K.; Vallbo, C.; Wang, W.; Damber, J. E. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate, 2005, 65 (2), 110-116.
136. Meister, B.; Grünebach, F.; Bautz, F.; Brugger, W.; Fink, F. M.; Kanz, L.; Möhle, R. Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur. J. Cancer, 1999, 35 (3), 445-449.
137. Fakhari, M.; Pullirsch, D.; Paya, K.; Abraham, D.; Hofbauer, R.; Aharinejad, S. Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J. Pediatr. Surg., 2002, 37 (4), 582-587.
138. Nowicki, M.; Konwerska, A.; Ostalska-Nowicka, D.; Derwich, K.; Miskowiak, B.; Kondraciuk, B.; Samulak, D.; Witt, M. Vascular endothelial growth factor (VEGF)-C -a potent risk factor in children diagnosed with stadium 4 neuroblastoma. Folia Histochem. Cytobiol., 2008, 46 (4), 493-499.
139. Lagodny, J.; Jüttner, E.; Kayser, G.; Niemeyer, C. M.; Rössler, J. Lymphangiogenesis and its regulation in human neuroblastoma. Biochem. Biophys. Res. Commun., 2007, 352 (2), 571-577.
140. Beierle, E. A.; Dai, W.; Langham, M. R.; Copeland, E. M.; Chen, M. K. Expression of VEGF receptors in cocultured neuroblastoma cells. J. Surg. Res., 2004, 119 (1), 56-65.
141. Beierle, E. A.; Dai, W.; Langham, M. R.; Copeland, E. M.; Chen, M. K. VEGF receptors are differentially expressed by neuroblastoma cells in culture. J. Pediatr. Surg., 2003, 38 (3), 514-521.
142. Langer, I.; Vertongen, P.; Perret, J.; Fontaine, J.; Atassi, G.; Robberecht, P. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med. Pediatr. Oncol., 2000, 34 (6), 386-393.
143. Beierle, E. A.; Strande, L. F.; Chen, M. K. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J. Pediatr. Surg., 2002, 37 (3), 467-471.
144. Rowe, D. H.; Huang, J.; Li, J.; Manley, C.; O'Toole, K. M.; Stolar, C. J.; Yamashiro, D. J.; Kandel, J. J. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J. Pediatr. Surg., 2000, 35 (6), 977-981.
145. Gomes, E.; Rockwell, P. p38 MAPK as a negative regulator of VEGF/VEGFR2 signaling pathway in serum deprived human SK-N-SH neuroblastoma cells. Neurosci. Lett., 2008, 431 (2), 95-100.
146. Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene, 2008, 27 (28), 3999-4007.
147. Segerström, L.; Fuchs, D.; Bäckman, U.; Holmquist, K.; Christofferson, R.; Azarbayjani, F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr. Res., 2006, 60 (5), 576-581.
148. Sims, T. L.; Williams, R. F.; Ng, C. Y.; Rosati, S. F.; Spence, Y.; Davidoff, A. M. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery, 2008, 144 (2), 269-275.
149. Dickson, P. V.; Hamner, J. B.; Sims, T. L.; Fraga, C. H.; Ng, C. Y.; Rajasekeran, S.; Hagedorn, N. L.; McCarville, M. B.; Stewart, C. F.; Davidoff, A. M. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res., 2007, 13 (13), 3942-3950.
150. Maris, J. M.; Courtright, J.; Houghton, P. J.; Morton, C. L.; Gorlick, R.; Kolb, E. A.; Lock, R.; Tajbakhsh, M.; Reynolds, C. P.; Keir, S. T.; Wu, J.; Smith, M. A. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2008, 50 (3), 581-587.
151. Rössler, J.; Monnet, Y.; Farace, F.; Opolon, P.; Daudigeos-Dubus, E.; Bourredjem, A.; Vassal, G.; Geoerger, B. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int. J. Cancer, 2011, 128 (11), 2748-2758.
152. Beaudry, P.; Nilsson, M.; Rioth, M.; Prox, D.; Poon, D.; Xu, L.; Zweidler-Mckay, P.; Ryan, A.; Folkman, J.; Ryeom, S.; Heymach, J. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol. Cancer Ther., 2008, 7 (2), 418-24.
153. Manders E.M.M.; Verbeek F.J.; Aten J.A. Measurement of colocalization of objects in dual-color confocal images. J. Microsc., 1993, 169, 375-382.